Allist(688578)2024-10-24 09:04Financial Performance - The company's operating revenue for Q3 2024 reached ¥957 million, representing a year-on-year increase of 59.73%[2] - Net profit attributable to shareholders for Q3 2024 was ¥407 million, up 101.38% compared to the same period last year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥364 million, reflecting an 85.44% increase year-on-year[2] - For the first nine months of 2024, total revenue reached CNY 2.533 billion, an increase of 87.97% compared to the same period last year[13] - Total operating revenue for the first three quarters of 2024 reached CNY 2,533,480,109.53, a significant increase from CNY 1,347,801,762.83 in the same period of 2023, representing an increase of approximately 88.1%[16] - Net profit for the first three quarters of 2024 was CNY 1,062,948,077.37, compared to CNY 410,427,066.86 in the same period of 2023, marking an increase of about 158.5%[16] - The company reported a total comprehensive income of CNY 1,118,116,117.50 for the first three quarters of 2024, compared to CNY 412,056,257.48 in 2023, which is an increase of approximately 171.5%[18] - Basic and diluted earnings per share for the first three quarters of 2024 were both CNY 2.36, compared to CNY 0.91 in the same period of 2023, representing an increase of approximately 159.3%[18] Research and Development - Research and development expenses totaled ¥234 million in Q3 2024, a significant increase of 198.76% compared to the same period last year[3] - The ratio of R&D expenses to operating revenue increased by 24.41 percentage points to 11.36%[3] - Research and development expenses for the first three quarters of 2024 totaled CNY 207,670,593.28, up from CNY 191,351,163.78 in 2023, indicating a growth of approximately 8.5%[16] - The company signed a licensing and development agreement with JAKOS for exclusive rights to develop KRAS G12C inhibitor and SHP2 inhibitor in China, expanding its oncology pipeline[13] - The company received approval from the National Medical Products Administration to conduct clinical trials for AST2303, a new generation EGFR oral inhibitor targeting EGFR C797S mutation[13] Assets and Liabilities - Total assets at the end of Q3 2024 amounted to ¥5.43 billion, a 24.14% increase from the end of the previous year[3] - As of September 30, 2024, total assets amounted to CNY 5.433 billion, up from CNY 4.376 billion at the end of 2023[15] - The company's total liabilities as of September 30, 2024, were CNY 570 million, compared to CNY 394 million at the end of 2023[15] - The company's retained earnings rose significantly from CNY 229 million to CNY 908 million compared to the previous year[15] - The company’s capital reserve increased from CNY 3.175 billion to CNY 3.230 billion year-over-year[15] Cash Flow and Operating Activities - Cash flow from operating activities for the year-to-date period reached ¥1.24 billion, up 167.71% year-on-year[2] - The net cash flow from operating activities for the first three quarters of 2024 was CNY 1,236,489,837.49, compared to CNY 461,873,407.41 in the same period of 2023, reflecting an increase of about 167.5%[19] - The company reported cash and cash equivalents of CNY 474,698,599.31 at the end of the third quarter of 2024, down from CNY 988,981,874.59 at the end of 2023, indicating a decrease of approximately 52.0%[19] - The cash and cash equivalents decreased from CNY 1.862 billion at the end of 2023 to CNY 717 million as of September 30, 2024[15] - The company received cash from sales and services amounting to CNY 2,791,421,304.47 in the first three quarters of 2024, compared to CNY 1,449,107,899.32 in the same period of 2023, an increase of approximately 92.7%[19] Strategic Initiatives - The company implemented cost reduction and efficiency improvement measures, contributing to a net profit increase[5] - The company plans to continue expanding its product offerings and market presence, particularly in the area of innovative drug development[6] Accounting and Reporting - The company has adopted new accounting standards starting in 2024, impacting the financial statements from the beginning of the year[20] - The third quarter report was officially announced on October 25, 2024[21]